|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.45 DKK | +1.48% |
|
-0.36% | -15.54% |
| 29/04 | Nordea cuts Embla price target to DKK 34 (38), reiterates Buy | FW |
| 28/04 | Embla Medical hf., Q1 2026 Earnings Call, Apr 28, 2026 |
Company Valuation: Embla Medical hf.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,720 | 2,025 | 1,711 | 2,115 | 2,187 | 1,822 | - | - |
| Change | - | -25.54% | -15.52% | 23.63% | 3.42% | -16.73% | - | - |
| Enterprise Value (EV) 1 | 3,083 | 2,429 | 2,106 | 2,529 | 2,626 | 2,217 | 2,174 | 2,130 |
| Change | - | -21.2% | -13.31% | 20.1% | 3.84% | -15.6% | -1.93% | -2% |
| P/E ratio | 41.1x | 47.6x | 28.4x | 30.6x | 26.2x | 19.5x | 16.6x | 14.3x |
| PBR | 4.33x | 3.26x | 2.38x | 2.73x | 2.46x | 1.86x | 1.69x | 1.52x |
| PEG | - | -1.5x | 0.8x | 1.5x | 4.07x | 1.4x | 1x | 0.9x |
| Capitalization / Revenue | 3.78x | 2.82x | 2.18x | 2.47x | 2.36x | 1.78x | 1.65x | 1.52x |
| EV / Revenue | 4.29x | 3.38x | 2.68x | 2.96x | 2.83x | 2.17x | 1.97x | 1.78x |
| EV / EBITDA | 20.7x | 19x | 15.1x | 14.6x | 14.1x | 10.6x | 9.37x | 8.28x |
| EV / EBIT | 31.7x | 30.8x | 23.6x | 22.4x | 21x | 15.6x | 13.6x | 11.9x |
| EV / FCF | 41.7x | 69.4x | 40.5x | 32.8x | 26.3x | 22.2x | 18.2x | 16.8x |
| FCF Yield | 2.4% | 1.44% | 2.47% | 3.04% | 3.81% | 4.51% | 5.48% | 5.96% |
| Dividend per Share 3 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 3 | 1.03 | 0.7053 | 0.9656 | 1.164 | 1.239 | 1.41 | 1.649 | 1.919 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 718.7 | 718.6 | 785.7 | 854.9 | 928.7 | 1,022 | 1,105 | 1,197 |
| EBITDA 1 | 149 | 128.2 | 139.3 | 173.3 | 185.9 | 209.8 | 232 | 257.4 |
| EBIT 1 | 97.31 | 78.84 | 89.39 | 113.2 | 125.3 | 142.1 | 159.5 | 179.6 |
| Net income 1 | 63.99 | 42.51 | 58.39 | 68.28 | 83.34 | 94.5 | 109.9 | 126.2 |
| Net Debt 1 | 363 | 404 | 395 | 414 | 439 | 395.1 | 352.4 | 308.9 |
| Reference price 3 | 42.30 | 33.55 | 27.45 | 35.60 | 32.50 | 27.45 | 27.45 | 27.45 |
| Nbr of stocks (in thousands) | 4,22,208 | 4,20,145 | 4,20,298 | 4,26,934 | 4,27,326 | 4,26,703 | - | - |
| Announcement Date | 01/02/22 | 31/01/23 | 30/01/24 | 05/02/25 | 03/02/26 | - | - | - |
1DKK in Million2USD in Million3DKK
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 19.46x | 2.17x | 10.57x | -.--% | 180.94Cr | ||
| 31.39x | 5.36x | 17.96x | 1.08% | 1.89TCr | ||
| 20.7x | 3.42x | 12.56x | 2.25% | 1.56TCr | ||
| 25.95x | 2.74x | 13.02x | 3.42% | 464.52Cr | ||
| 19.12x | 2.47x | 9.58x | 1.96% | 404.19Cr | ||
| 49.82x | 3.05x | 24.26x | 0.92% | 154.86Cr | ||
| 19.49x | 4.19x | 12.1x | 1.03% | 118.31Cr | ||
| -17.83x | - | - | - | 37Cr | ||
| Average | 21.01x | 3.34x | 14.29x | 1.52% | 600.81Cr | |
| Weighted average by Cap. | 25.83x | 4.00x | 14.78x | 1.72% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- EMBLA Stock
- Valuation Embla Medical hf.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















